Novel therapeutic targets in myeloma bone disease.

Journal article

Multiple myeloma is a neoplastic disorder of plasma cells characterized by clonal proliferation within the bone marrow. One of the major clinical features of multiple myeloma is the destructive osteolytic bone disease that occurs in the majority of patients. Myeloma bone disease is associated with increased osteoclast activity and suppression of osteoblastogenesis. Bisphosphonates have been the mainstay of treatment for many years; however, their use is limited by their inability to repair existing bone loss. Therefore, research into novel approaches for the treatment of myeloma bone disease is of the utmost importance. This review will discuss the current advances in our understanding of osteoclast stimulation and osteoblast suppression mechanisms in myeloma bone disease and the treatments that are under development to target this destructive and debilitating feature of myeloma.

Authors: Webb, S; Edwards, C

• Publication status: Published
• Publisher: John Wiley and Sons Inc.
• Journal: British journal of pharmacology
• Volume: 171
• Issue: 16
• Pages: 3765-3776
• Publication date: 2014-08-01
• DOI: 10.1111/bph.12742
• EISSN: 1476-5381
• ISSN: 0007-1188
• Language: English